Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus TP in neoadjuvant breast cancer
NCT03580395Phase 3
Key facts
- Status
- Unknown
- Start
- Jun 2017
- Primary completion
- Jul 2022
- Countries
- 1
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Modality
- Small Molecules
- Drugs
- Rivoceranib
- Conditions
- breast cancer
01
Overview
Phase 3, randomised, open-label trial of Rivoceranib in breast cancer (2 arms), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Pathological Complete Remission at 4 months. Status: unknown.
02
Design
2 arms- Study design
- RandomizedOpen-label
apatinib+TP
Apatinib 500mg daily + Paclitaxel 165mg/m2 + Cisplatin 40mg
TP
Paclitaxel 165mg/m2 + Cisplatin 40mg
03
Who it enrols
Female patients aged 18-70 with stage IIb-IIIc invasive breast cancer (Triple-negative, HER2+, or Luminal B) planned for neoadjuvant therapy, with adequate organ function and no prior breast cancer treatment.
04
Endpoints
Primary
Pathological Complete Remission
Secondary
Objective Response Rate
Adverse Events
Beyond the preview
Go deeper on NCT03580395.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03580395.